PharmaCyte Biotech Inc (PMCB)

[longboarder7892]

We are also contemplating a reverse stock split and a possible up-listing of our common stock to The Nasdaq Capital Market (“Nasdaq”). Nasdaq requires that the bid price of the common stock must have a closing bid price of at least $4.00 per share in connection with an up-listing. An up-listing of our common stock to Nasdaq could potentially bring many benefits to the Company and its investors, including broadening the appeal of our shares to institutional investors, improving liquidity for our shareholders, potentially facilitating our ability to raise capital through offerings of our common stock and equity linked securities as well as increasing our visibility in the broader investment community. No assurance can be given that we will effect a reverse stock split and an uplisting of our common stock to Nasdaq.